Section of Pulmonary Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Curr Opin Pulm Med. 2010 Jan;16(1):42-7. doi: 10.1097/MCP.0b013e328332ca46.
The fraction of nitric oxide in exhaled air (FeNO) is elevated in the presence of airway inflammation, and it may be a useful biomarker in asthma. The purpose of the present review is to highlight the current literature investigating the use of exhaled nitric oxide in the diagnosis and management of asthma.
The measurement of exhaled nitric oxide has been studied in normal populations and in asthmatics. FeNO appears to be a useful screening tool for asthma, although nondisease factors may confound the interpretation of an elevated FeNO level. Clinical trials investigating the use of FeNO measurements in predicting asthma exacerbation and tailoring maintenance therapy have had varying success. Further studies incorporating individualized FeNO profiles into treatment algorithms are needed.
FeNO shows promise as a tool in the diagnosis and treatment of asthma. However, further studies are needed to address outstanding questions about its exact role in guiding asthma management.
呼出气一氧化氮（FeNO）分数在气道炎症存在时升高，它可能是哮喘的有用生物标志物。本综述的目的是强调目前关于呼出气一氧化氮在哮喘诊断和管理中的应用的文献。
已经在正常人群和哮喘患者中研究了呼出气一氧化氮的测量。FeNO 似乎是哮喘的有用筛查工具，尽管非疾病因素可能会混淆升高的 FeNO 水平的解释。临床试验研究了 FeNO 测量在预测哮喘恶化和调整维持治疗中的作用，结果不尽相同。需要进一步的研究将个体化的 FeNO 谱纳入治疗算法中。
FeNO 作为哮喘诊断和治疗的一种工具具有很大的应用前景。然而，需要进一步的研究来解决关于其在指导哮喘管理中的确切作用的一些尚未解决的问题。
